UA79666C2 - 1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders - Google Patents

1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders Download PDF

Info

Publication number: UA79666C2
Authority: UA; Ukraine
Prior art keywords: amino; alk; ylmethyl; phenyl; carbamic acid
Prior art date: 2002-12-27

Application number

UAA200507206A

Other languages

English (en)

Ukrainian (uk)

Inventor

Mario Rottlonder

Andreas Ritzen

Noergaard Morten Bang

Nikolay Khanzhin

Tornoee Christian Wenzel

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2003-12-18

Publication date

2007-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35295526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA79666(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-18 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2003-12-18 Priority claimed from PCT/DK2003/000906 external-priority patent/WO2004058739A1/en

2007-07-10 Publication of UA79666C2 publication Critical patent/UA79666C2/uk

Links

JSYBAZQQYCNZJE-UHFFFAOYSA-N benzene-1,2,4-triamine Chemical class NC1=CC=C(N)C(N)=C1 JSYBAZQQYCNZJE-UHFFFAOYSA-N 0.000 title claims abstract description 6
208000015114 central nervous system disease Diseases 0.000 title claims 3
150000003839 salts Chemical class 0.000 claims abstract description 35
150000001875 compounds Chemical class 0.000 claims description 277
125000004494 ethyl ester group Chemical group 0.000 claims description 96
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 90
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 66
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 44
125000003118 aryl group Chemical group 0.000 claims description 35
206010010904 Convulsion Diseases 0.000 claims description 32
125000001424 substituent group Chemical group 0.000 claims description 28
229920006395 saturated elastomer Polymers 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 21
208000019901 Anxiety disease Diseases 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
208000004296 neuralgia Diseases 0.000 claims description 17
208000021722 neuropathic pain Diseases 0.000 claims description 17
125000005843 halogen group Chemical group 0.000 claims description 16
125000002252 acyl group Chemical group 0.000 claims description 14
206010015037 epilepsy Diseases 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
230000002265 prevention Effects 0.000 claims description 13
125000005842 heteroatom Chemical group 0.000 claims description 12
230000004770 neurodegeneration Effects 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 12
125000005605 benzo group Chemical group 0.000 claims description 11
210000003169 central nervous system Anatomy 0.000 claims description 11
239000003085 diluting agent Substances 0.000 claims description 11
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 10
230000036461 convulsion Effects 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 10
125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
210000002569 neuron Anatomy 0.000 claims description 9
206010001497 Agitation Diseases 0.000 claims description 8
208000014644 Brain disease Diseases 0.000 claims description 8
208000032274 Encephalopathy Diseases 0.000 claims description 8
208000019695 Migraine disease Diseases 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
206010027599 migraine Diseases 0.000 claims description 8
125000004434 sulfur atom Chemical group 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
229910052717 sulfur Inorganic materials 0.000 claims description 7
208000011688 Generalised anxiety disease Diseases 0.000 claims description 6
208000029364 generalized anxiety disease Diseases 0.000 claims description 6
208000008811 Agoraphobia Diseases 0.000 claims description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
208000002193 Pain Diseases 0.000 claims description 5
206010034912 Phobia Diseases 0.000 claims description 5
206010041250 Social phobia Diseases 0.000 claims description 5
208000026345 acute stress disease Diseases 0.000 claims description 5
208000012826 adjustment disease Diseases 0.000 claims description 5
230000036506 anxiety Effects 0.000 claims description 5
125000004093 cyano group Chemical group *C#N 0.000 claims description 5
208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
201000001716 specific phobia Diseases 0.000 claims description 5
208000005809 status epilepticus Diseases 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
208000004454 Hyperalgesia Diseases 0.000 claims description 4
201000001916 Hypochondriasis Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
208000004983 Phantom Limb Diseases 0.000 claims description 4
206010056238 Phantom pain Diseases 0.000 claims description 4
241000710799 Rubella virus Species 0.000 claims description 4
241000589970 Spirochaetales Species 0.000 claims description 4
206010053552 allodynia Diseases 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
230000035987 intoxication Effects 0.000 claims description 4
231100000566 intoxication Toxicity 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
244000052769 pathogen Species 0.000 claims description 4
230000001629 suppression Effects 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
241001529453 unidentified herpesvirus Species 0.000 claims description 4
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
208000000810 Separation Anxiety Diseases 0.000 claims description 3
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
125000001072 heteroaryl group Chemical group 0.000 claims description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims 2
239000000825 pharmaceutical preparation Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
239000000203 mixture Substances 0.000 description 70
239000000243 solution Substances 0.000 description 59
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 36
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
235000019439 ethyl acetate Nutrition 0.000 description 36
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
239000002253 acid Substances 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
239000002904 solvent Substances 0.000 description 27
-1 -CO-ME 985 Chemical group 0.000 description 26
238000000034 method Methods 0.000 description 26
239000007787 solid Substances 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
108091006146 Channels Proteins 0.000 description 18
239000000047 product Substances 0.000 description 18
238000012360 testing method Methods 0.000 description 17
239000007864 aqueous solution Substances 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
108020001213 potassium channel Proteins 0.000 description 15
102000004257 Potassium Channel Human genes 0.000 description 14
229960000583 acetic acid Drugs 0.000 description 14
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 13
229960003312 retigabine Drugs 0.000 description 13
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000000725 suspension Substances 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
230000001773 anti-convulsant effect Effects 0.000 description 11
239000003480 eluent Substances 0.000 description 11
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
239000001961 anticonvulsive agent Substances 0.000 description 10
239000012043 crude product Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
230000003993 interaction Effects 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
239000003638 chemical reducing agent Substances 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
239000000654 additive Substances 0.000 description 7
150000001299 aldehydes Chemical class 0.000 description 7
229960003965 antiepileptics Drugs 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
230000002920 convulsive effect Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000011591 potassium Substances 0.000 description 7
229910052700 potassium Inorganic materials 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
239000002585 base Substances 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
229910052801 chlorine Inorganic materials 0.000 description 6
238000011161 development Methods 0.000 description 6
238000010828 elution Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
150000002466 imines Chemical class 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
239000002245 particle Substances 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
239000012266 salt solution Substances 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
239000012279 sodium borohydride Substances 0.000 description 6
229910000033 sodium borohydride Inorganic materials 0.000 description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 5
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
239000008346 aqueous phase Substances 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
229960001416 pilocarpine Drugs 0.000 description 5
239000012256 powdered iron Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
238000005932 reductive alkylation reaction Methods 0.000 description 5
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
206010036105 Polyneuropathy Diseases 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
150000001805 chlorine compounds Chemical class 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000012528 membrane Substances 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000012047 saturated solution Substances 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229940083542 sodium Drugs 0.000 description 4
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
229930192474 thiophene Natural products 0.000 description 4
125000005270 trialkylamine group Chemical group 0.000 description 4
MVCZOBCFLDNDPO-UHFFFAOYSA-N (4-amino-2-nitrophenyl)carbamic acid Chemical compound [N+](=O)([O-])C1=C(C=CC(=C1)N)NC(O)=O MVCZOBCFLDNDPO-UHFFFAOYSA-N 0.000 description 3
IQFUADQPSYSDIP-UHFFFAOYSA-N (4-aminophenyl)carbamic acid Chemical compound NC1=CC=C(NC(O)=O)C=C1 IQFUADQPSYSDIP-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
YYCSWRCBRDKMCM-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC(=C(C=C3)NC(=O)O)[N+](=O)[O-] Chemical compound C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC(=C(C=C3)NC(=O)O)[N+](=O)[O-] YYCSWRCBRDKMCM-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
210000004727 amygdala Anatomy 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
238000009835 boiling Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000003749 cleanliness Effects 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
230000004907 flux Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
235000013675 iodine Nutrition 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
239000003826 tablet Substances 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
HVHNMNGARPCGGD-UHFFFAOYSA-N 2-nitro-p-phenylenediamine Chemical compound NC1=CC=C(N)C([N+]([O-])=O)=C1 HVHNMNGARPCGGD-UHFFFAOYSA-N 0.000 description 2
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
LUAQHOIIXDJUOY-UHFFFAOYSA-N 5-fluoro-1-benzofuran-3-carbaldehyde Chemical compound FC1=CC=C2OC=C(C=O)C2=C1 LUAQHOIIXDJUOY-UHFFFAOYSA-N 0.000 description 2
KURANAVGCJMDFR-UHFFFAOYSA-N 5-fluorothiophene-2-carbaldehyde Chemical compound FC1=CC=C(C=O)S1 KURANAVGCJMDFR-UHFFFAOYSA-N 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010011878 Deafness Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010029240 Neuritis Diseases 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000036982 action potential Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940125681 anticonvulsant agent Drugs 0.000 description 2
125000005129 aryl carbonyl group Chemical group 0.000 description 2
230000001977 ataxic effect Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
229910052792 caesium Inorganic materials 0.000 description 2
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000007705 chemical test Methods 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
231100000895 deafness Toxicity 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
210000002768 hair cell Anatomy 0.000 description 2
208000016354 hearing loss disease Diseases 0.000 description 2
150000002390 heteroarenes Chemical class 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000002631 hypothermal effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
229940078552 o-xylene Drugs 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
210000002741 palatine tonsil Anatomy 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
230000008447 perception Effects 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
208000019629 polyneuritis Diseases 0.000 description 2
230000007824 polyneuropathy Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
229940081974 saccharin Drugs 0.000 description 2
235000019204 saccharin Nutrition 0.000 description 2
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 2
230000001256 tonic effect Effects 0.000 description 2
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
VXVFDCLRTBRSNI-UHFFFAOYSA-N (4-amino-3-nitrophenyl)carbamic acid Chemical compound NC1=CC=C(NC(O)=O)C=C1[N+]([O-])=O VXVFDCLRTBRSNI-UHFFFAOYSA-N 0.000 description 1
OIXUJRCCNNHWFI-UHFFFAOYSA-N 1,2-dioxane Chemical compound C1CCOOC1 OIXUJRCCNNHWFI-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
DXHCHIJMMKQRKR-UHFFFAOYSA-N 2-fluorothiophene Chemical compound FC1=CC=CS1 DXHCHIJMMKQRKR-UHFFFAOYSA-N 0.000 description 1
ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
PFINICYHLWOWLU-UHFFFAOYSA-N 4-(4-chlorophenyl)sulfonyl-3-methylthiophene-2-carbaldehyde Chemical compound CC1=C(C=O)SC=C1S(=O)(=O)C1=CC=C(Cl)C=C1 PFINICYHLWOWLU-UHFFFAOYSA-N 0.000 description 1
YMLAKKSHBUZQFA-UHFFFAOYSA-N 4-bromo-3-hydroxythiophene-2-carboxylic acid Chemical compound OC(=O)C=1SC=C(Br)C=1O YMLAKKSHBUZQFA-UHFFFAOYSA-N 0.000 description 1
IMZHEINQYLNZLJ-UHFFFAOYSA-N 4-bromo-3-methoxythiophene-2-carbaldehyde Chemical compound COC=1C(Br)=CSC=1C=O IMZHEINQYLNZLJ-UHFFFAOYSA-N 0.000 description 1
VAUMDUIUEPIGHM-UHFFFAOYSA-N 5-Methyl-2-thiophenecarboxaldehyde Chemical compound CC1=CC=C(C=O)S1 VAUMDUIUEPIGHM-UHFFFAOYSA-N 0.000 description 1
VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
MVEOHWRUBFWKJY-UHFFFAOYSA-N 7-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=CC2=CC(O)=CC=C21 MVEOHWRUBFWKJY-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
206010053398 Clonic convulsion Diseases 0.000 description 1
208000033001 Complex partial seizures Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
208000002877 Epileptic Syndromes Diseases 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100028171 Homeobox-containing protein 1 Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001006354 Homo sapiens Homeobox-containing protein 1 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
229910013868 M2SO4 Inorganic materials 0.000 description 1
241000894339 Matucare virus Species 0.000 description 1
101100241859 Mus musculus Oacyl gene Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000002059 anti-epileptogenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000006400 anxiety behaviour Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
125000005418 aryl aryl group Chemical group 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000003477 cochlea Anatomy 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
238000010586 diagram Methods 0.000 description 1
GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000005611 electricity Effects 0.000 description 1
230000008918 emotional behaviour Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000001037 epileptic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
229960002767 ethosuximide Drugs 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
HDEBGAGNWSBAOY-UHFFFAOYSA-N ethyl n-(4-amino-2-nitrophenyl)carbamate Chemical compound CCOC(=O)NC1=CC=C(N)C=C1[N+]([O-])=O HDEBGAGNWSBAOY-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000011686 genetic mapping animal model Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
229960001848 lamotrigine Drugs 0.000 description 1
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
229960004002 levetiracetam Drugs 0.000 description 1
HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000017813 membrane repolarization Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
QYCQNXGCCPPUIT-UHFFFAOYSA-N methyl 4-(4-chlorophenyl)sulfonyl-3-methylthiophene-2-carboxylate Chemical compound CC1=C(C(=O)OC)SC=C1S(=O)(=O)C1=CC=C(Cl)C=C1 QYCQNXGCCPPUIT-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
229960001233 pregabalin Drugs 0.000 description 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
210000001176 projection neuron Anatomy 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000018448 secretion by cell Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000031893 sensory processing Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003577 thiophenes Chemical class 0.000 description 1
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
229960001918 tiagabine Drugs 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960004394 topiramate Drugs 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000001213 vestibule labyrinth Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
229960002911 zonisamide Drugs 0.000 description 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA200507206A 2002-12-27 2003-12-18 1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders UA79666C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200202012		2002-12-27
PCT/DK2003/000906 WO2004058739A1 (en)	2002-12-27	2003-12-18	1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system

Publications (1)

Publication Number	Publication Date
UA79666C2 true UA79666C2 (en)	2007-07-10

Family

ID=35295526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200507206A UA79666C2 (en)	2002-12-27	2003-12-18	1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders

Country Status (16)

Country	Link
KR (1)	KR20050089862A (pl)
CN (1)	CN100448867C (pl)
AR (1)	AR042656A1 (pl)
BR (1)	BR0317748A (pl)
CL (1)	CL2003002748A1 (pl)
EA (1)	EA008589B1 (pl)
IS (1)	IS2649B (pl)
MY (1)	MY139844A (pl)
NO (1)	NO20053612L (pl)
PE (1)	PE20041015A1 (pl)
PL (1)	PL377221A1 (pl)
SI (1)	SI1578740T1 (pl)
TW (1)	TWI325414B (pl)
UA (1)	UA79666C2 (pl)
UY (1)	UY28151A1 (pl)
ZA (1)	ZA200504565B (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4200259A1 (de) *	1992-01-08	1993-07-15	Asta Medica Ag	Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) *	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) *	1999-07-01	1999-09-01	Glaxo Group Ltd	Medical use
US6117900A (en) *	1999-09-27	2000-09-12	Asta Medica Aktiengesellschaft	Use of retigabine for the treatment of neuropathic pain
US6589986B2 (en) *	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders

2003
- 2003-12-18 KR KR1020057012183A patent/KR20050089862A/ko not_active Ceased
- 2003-12-18 PL PL377221A patent/PL377221A1/pl unknown
- 2003-12-18 BR BR0317748-3A patent/BR0317748A/pt not_active IP Right Cessation
- 2003-12-18 CN CNB2003801076953A patent/CN100448867C/zh not_active Expired - Fee Related
- 2003-12-18 EA EA200501053A patent/EA008589B1/ru not_active IP Right Cessation
- 2003-12-18 SI SI200330827T patent/SI1578740T1/sl unknown
- 2003-12-18 UA UAA200507206A patent/UA79666C2/uk unknown
- 2003-12-18 TW TW092135930A patent/TWI325414B/zh not_active IP Right Cessation
- 2003-12-22 AR ARP030104782A patent/AR042656A1/es unknown
- 2003-12-24 CL CL200302748A patent/CL2003002748A1/es unknown
- 2003-12-24 UY UY28151A patent/UY28151A1/es not_active Application Discontinuation
- 2003-12-26 MY MYPI20035008A patent/MY139844A/en unknown
2004
- 2004-01-05 PE PE2004000037A patent/PE20041015A1/es not_active Application Discontinuation
2005
- 2005-05-23 IS IS7856A patent/IS2649B/is unknown
- 2005-06-03 ZA ZA200504565A patent/ZA200504565B/xx unknown
- 2005-07-25 NO NO20053612A patent/NO20053612L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0317748A (pt)	2005-11-22
IS7856A (is)	2005-05-23
CN100448867C (zh)	2009-01-07
PL377221A1 (pl)	2006-01-23
ZA200504565B (en)	2006-08-30
NO20053612D0 (no)	2005-07-25
KR20050089862A (ko)	2005-09-08
AR042656A1 (es)	2005-06-29
SI1578740T1 (sl)	2007-08-31
NO20053612L (no)	2005-09-23
TWI325414B (en)	2010-06-01
TW200413280A (en)	2004-08-01
UY28151A1 (es)	2004-07-30
PE20041015A1 (es)	2005-01-08
IS2649B (is)	2010-08-15
EA200501053A1 (ru)	2005-12-29
CN1732162A (zh)	2006-02-08
CL2003002748A1 (es)	2005-04-08
HK1088317A1 (zh)	2006-11-03
MY139844A (en)	2009-11-30
EA008589B1 (ru)	2007-06-29

Publication	Publication Date	Title
CN114945566B (zh)	2024-11-12	作为钠通道调节剂的取代四氢呋喃
CN105814067B (zh)	2018-05-18	作为钠通道调节剂的吡啶酮酰胺的前药
CN104203914B (zh)	2017-07-11	作为lsd1抑制剂的(杂)芳基环丙胺化合物
EP1697308B1 (en)	2014-03-19	Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
JP2021038263A (ja)	2021-03-11	治療上活性な化合物およびそれらの使用方法
JP2006526590A (ja)	2006-11-24	マトリックスメタロプロテイナーゼ阻害剤
JP2000516955A (ja)	2000-12-19	置換環状アミンメタロプロテアーゼ阻害剤
WO2023034992A1 (en)	2023-03-09	Indole compounds and methods of use
KR20060128004A (ko)	2006-12-13	치환된 모르폴린 및 티오모르폴린 유도체
EA025635B1 (ru)	2017-01-30	Производные имидазопиридазина в качестве модуляторов gabaa рецепторов
EP3807261B1 (en)	2022-07-13	Pyridinyl pyrazoles as modulators of roryt
MX2012014131A (es)	2013-01-29	Compuestos heterociclicos de benzodioxol o benzodioxepina como inhibidores de fosfodiesterasa.
JPH02290841A (ja)	1990-11-30	新規化合物、その製法及びそれを含む医薬組成物
TW202003472A (zh)	2020-01-16	鈣蛋白酶(calpain)調節劑及其醫療用途
JP2009514802A (ja)	2009-04-09	ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
CA2992410A1 (en)	2017-02-23	Hydroxytriazine compounds and pharmaceutical use thereof
CN112513011B (zh)	2023-06-16	苯衍生物
WO2022237780A1 (zh)	2022-11-17	酰胺衍生物及其应用
KR20050106421A (ko)	2005-11-09	카르복실산 화합물
HK1254800A1 (zh)	2019-07-26	2，3，4，5-四氢吡啶-6-胺衍生物
WO2004011470A1 (ja)	2004-02-05	フロイソキノリン誘導体およびその用途
UA81799C2 (uk)	2008-02-11	Заміщені похідні аніліну
KR102121680B1 (ko)	2020-06-10	설파메이트 유도체 화합물, 이의 제조 방법 및 용도
CN114539237B (zh)	2023-05-23	Ido抑制剂、制备方法、药物组合物和应用
UA79666C2 (en)	2007-07-10	1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders